<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 10 Apr 2021 07:23:47 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>康柏西普：国际三期临床失败</title><link>https://mp.weixin.qq.com/s/KkQWc1hUtvjojpKVbMXzzw</link><description></description><content:encoded><![CDATA[康柏西普：国际三期临床失败]]></content:encoded><pubDate>Fri, 09 Apr 2021 22:27:58 +0800</pubDate></item><item><title>恒瑞医药申报TSLP抗体，国内第2家</title><link>https://mp.weixin.qq.com/s/Ot6p8tsorm84nZFcVaJUiA</link><description></description><content:encoded><![CDATA[恒瑞医药申报TSLP抗体，国内第2家]]></content:encoded><pubDate>Fri, 09 Apr 2021 22:27:58 +0800</pubDate></item><item><title>康诺亚递表港股IPO，C轮融资后估值7.81亿美元</title><link>https://mp.weixin.qq.com/s/DVGlH0U5d5VMLX_xr4rIYQ</link><description></description><content:encoded><![CDATA[康诺亚递表港股IPO，C轮融资后估值7.81亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 00:06:49 +0800</pubDate></item><item><title>腾盛博药递表港股IPO，C轮融资后估值14.55亿美元</title><link>https://mp.weixin.qq.com/s/ViMszDsDIrJfXunCI9bl8g</link><description></description><content:encoded><![CDATA[腾盛博药递表港股IPO，C轮融资后估值14.55亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 00:06:49 +0800</pubDate></item><item><title>疫苗百年史</title><link>https://mp.weixin.qq.com/s/8EW5At_YgMC6sy1oBMOynw</link><description></description><content:encoded><![CDATA[疫苗百年史]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>一型糖尿病新靶点：SerpinB13</title><link>https://mp.weixin.qq.com/s/auFVEqY68-Zn_ZlzF9XbuQ</link><description></description><content:encoded><![CDATA[一型糖尿病新靶点：SerpinB13]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>肝癌治疗新靶点：HDAC8</title><link>https://mp.weixin.qq.com/s/5TzaWlHD0HvhxESx1XUCEA</link><description></description><content:encoded><![CDATA[肝癌治疗新靶点：HDAC8]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>磷酸酶靶点：SHP2、PP2A、PRL3......</title><link>https://mp.weixin.qq.com/s/7wzjmH9InDPofuFUdknCJA</link><description></description><content:encoded><![CDATA[磷酸酶靶点：SHP2、PP2A、PRL3......]]></content:encoded><pubDate>Thu, 08 Apr 2021 06:59:59 +0800</pubDate></item><item><title>Nature：胃癌精准治疗新时代</title><link>https://mp.weixin.qq.com/s/GxCPQugRoU9pKDwZj1RB1w</link><description></description><content:encoded><![CDATA[Nature：胃癌精准治疗新时代]]></content:encoded><pubDate>Wed, 07 Apr 2021 06:59:11 +0800</pubDate></item><item><title>天境生物与吉凯基因合作开发双抗</title><link>https://mp.weixin.qq.com/s/WWsSE0HtdqJBrk6dWD4pAg</link><description></description><content:encoded><![CDATA[天境生物与吉凯基因合作开发双抗]]></content:encoded><pubDate>Wed, 07 Apr 2021 06:59:11 +0800</pubDate></item><item><title>抗流感ADC：强生与Cidara达成7.8亿美元合作</title><link>https://mp.weixin.qq.com/s/fhFkZ8uI2xG_xRDh0ue6NA</link><description></description><content:encoded><![CDATA[抗流感ADC：强生与Cidara达成7.8亿美元合作]]></content:encoded><pubDate>Tue, 06 Apr 2021 14:31:15 +0800</pubDate></item><item><title>小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和</title><link>https://mp.weixin.qq.com/s/tbknVOk0j9S_ZI1PuAGGlg</link><description></description><content:encoded><![CDATA[小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和]]></content:encoded><pubDate>Mon, 05 Apr 2021 07:49:45 +0800</pubDate></item><item><title>自身免疫新靶点：趋化素受体ChemR23</title><link>https://mp.weixin.qq.com/s/6g8gfbHdh1FSihnurCZ8Tg</link><description></description><content:encoded><![CDATA[自身免疫新靶点：趋化素受体ChemR23]]></content:encoded><pubDate>Sun, 04 Apr 2021 07:39:17 +0800</pubDate></item><item><title>国内首款：多禧生物申报MUC1 ADC</title><link>https://mp.weixin.qq.com/s/1qD5g-ZJzYcCCyhqM55U0g</link><description></description><content:encoded><![CDATA[国内首款：多禧生物申报MUC1 ADC]]></content:encoded><pubDate>Sat, 03 Apr 2021 07:18:53 +0800</pubDate></item><item><title>创胜集团技术全梳理</title><link>https://mp.weixin.qq.com/s/n8v8TNhsQ3qDTuwz7gyIyA</link><description></description><content:encoded><![CDATA[创胜集团技术全梳理]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:31:45 +0800</pubDate></item><item><title>Science封面：David Baker利用纳米笼组装抗体</title><link>https://mp.weixin.qq.com/s/I6vsdy_ON7o8dKjqxouKIw</link><description></description><content:encoded><![CDATA[Science封面：David Baker利用纳米笼组装抗体]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:31:45 +0800</pubDate></item><item><title>Science：歇会儿再干活，CAR-T更高效</title><link>https://mp.weixin.qq.com/s/K2MK2Y5HQ-lFP6nButEH5A</link><description></description><content:encoded><![CDATA[Science：歇会儿再干活，CAR-T更高效]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:31:45 +0800</pubDate></item><item><title>中国生物医药行业的研发竞争</title><link>https://mp.weixin.qq.com/s/w2KxP9COVah5Wj41j1_yZg</link><description></description><content:encoded><![CDATA[中国生物医药行业的研发竞争]]></content:encoded><pubDate>Thu, 01 Apr 2021 09:23:33 +0800</pubDate></item><item><title>君实生物申报CTLA-4抗体</title><link>https://mp.weixin.qq.com/s/AdodJTo8oTqbaNJbko90lg</link><description></description><content:encoded><![CDATA[君实生物申报CTLA-4抗体]]></content:encoded><pubDate>Thu, 01 Apr 2021 09:23:33 +0800</pubDate></item><item><title>肿瘤免疫新靶点：PLA2</title><link>https://mp.weixin.qq.com/s/2nMXE0IR1FnFaNWjlkV0dg</link><description></description><content:encoded><![CDATA[肿瘤免疫新靶点：PLA2]]></content:encoded><pubDate>Thu, 01 Apr 2021 09:23:33 +0800</pubDate></item></channel></rss>